PTGS2 and cancer: Several studies that evaluated the use of COX-2 inhibitors in cancer therapy showed that the antitumor effects of these agents were independent from their ability to inhibit COX-2, therefore new agents that retained the antitumor activity but had minor side effects compared with COX-2 inhibitors were developed [149].